PMH50 THE ROLE OF PRE-TREATMENT EXPECTANCY ON THE OUTCOME OF PRIMARY CARE TREATMENTS FOR DEPRESSION  by Gerhards, SAH et al.
larly, 78.3% of SSRI users and 81.3% of SNRI users were both-
ered by having little interest or pleasure in doing things equating
to 5.42 and 1.19 million in the larger population, respectively.
Unmet needs signiﬁcantly (p < 0.01) varied by country among
SSRI users but not SNRI users. CONCLUSIONS: Patient-
reported survey data reﬂect patients’ disease perception and are
generalizable to the population. These data show very high
unmet needs among patients with depression using SSRIs or
SNRIs in the ﬁve European countries and illustrates the remain-
ing need for treatments which can better alleviate depression
symptoms.
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OBJECTIVES: The purpose of this research is to determine if a
24-hour telephonic hotline is associated with lower post treat-
ment relapse rates for adolescents treated for psychoactive sub-
stance use disorder (PSUD). METHODS: Subjects are 246
adolescents discharged from primary substance abuse treatment
from 2005–2006. A total of 130 were discharged before imple-
mentation of the hotline and 116 were discharged after its imple-
mentation. The survey was based on a 234-item questionnaire.
Response rate was 62%. Treatment records of adolescents com-
pleting the questionnaire were obtained so treatment outcomes
from the questionnaire could be matched to variables contained
in treatment records. A comprehensive data set was created from
these two sources. Data are analyzed using three Cox regression
models. The ﬁrst model includes all 246 subjects using, as cova-
riates, psychosocial and treatment characteristics associated with
abstinence. The effects of the hotline (not available versus avail-
able) is compared by means of a stratiﬁcation variable yielding
two separate survival functions. Model two includes those
without access to the hotline and model three includes those with
access to the hotline. RESULTS: Model one indicates a better
cumulative survival function for those with access to the hotline
(Chi-square 46.9 p = 0.085). In model two (Chi-square 53.2 p =
0.025), boys and those diagnosed with alcohol abuse/dependence
are 2.8 and 3.5 times more likely to relapse (respectively), and
those on probation, those attending support groups and those
with supportive friends, are 51.2, 82.1, and 10.7% less likely to
relapse (respectively). In model three (Chi-square 49.3 p <
0.000), gender, diagnosis of alcohol abuse/dependence, and pro-
bation status, support group attendance and peer-support were
at parity. CONCLUSIONS: The telephone hotline is associated
with lower post treatment relapse rates, may improve the odds
that boys and those with alcohol abuse/dependence remain absti-
nent, and may lessen the inﬂuence of support groups and peer-
support on abstinence.
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OBJECTIVES: To improve the breadth and depth of the clinical
assessment of depressive symptomatology, a combined interview
of the 17-item Structured Interview Guide for the Hamilton
Depression Rating Scale (SIGH-D) and the 30-item Clinician
Rated Inventory of Depressive Symptomatology (IDS-C) was
translated into 20 languages. A rigorous methodology ensured
conceptual equivalence and cultural relevance across different
languages for this clinician-rated instrument. METHODS: For
languages where no translation of the existing scales was avail-
able, the translation process was conducted by a specialist in each
target country in collaboration with the developers of the two
instruments using the following methodology: 1) two forward
translations and reconciliation; 2) one backward translation; and
3) review by the sponsor’s subsidiaries. For languages where
translations of the existing scales were available, these were
integrated into the process as appropriate. RESULTS: Two chal-
lenges emerged: 1) The integration of available translations of
both existing scales required the challenging compromise of har-
monising possible divergence of wording for identical expres-
sions in the originals. The involvement of the developers of the
two existing scales was essential for this step; 2) The translation
of the original medical terms and their abbreviations were difﬁ-
cult or impossible to retain in certain target languages and para-
phrases approved by the developers had to be used. Examples
and solutions will be given during the presentation. CONCLU-
SIONS: The 20 translations of the combined interview were
established according to a rigorous methodology and in collabo-
ration with the developers of the existing scales to ensure con-
ceptual equivalence across languages. The psychometric analysis
of the data obtained from the combined interview will be neces-
sary to conﬁrm how these compare to those of the existing scales
both in the original and across languages.
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OBJECTIVES: Understanding determinants through which
health care interventions inﬂuence health outcomes may high-
light ways in which it can be maximized. This study explores the
role of pre-treatment credibility and expectancy on the outcome
of depression treatments in primary care. METHODS: Data are
used of a randomized trial comparing 1) computerized cognitive
behavioral therapy for depression (CCBT); with 2) treatment as
usual by a general practitioner (TAU); and 3) a combination of
both. Credibility and expectancy were assessed after treatment
allocation prior to treatment, with an adjusted and translated
version of the Credibility and Expectancy Questionnaire. Mod-
erators of expectancy and credibility are explored in a backward
linear regression analysis. The contribution of credibility and
expectancy to the severity of depression (BDI-II) and the quality-
of-life (SF-6D) outcome at 12 months after baseline is explored in
a stepwise linear regression, controlling for baseline depression
severity, baseline quality-of-life, sex, and age. RESULTS: The
type of intervention and educational level contribute to the level
of pre-treatment expectancy and credibility. No signiﬁcant asso-
ciation with credibility or expectancy was found for sex, age,
partner, employment status, baseline quality-of-life, baseline
severity of depression, and the presence of previous depressive
episodes during lifetime. In the CCBT and the TAU groups,
pre-treatment expectancy was associated with the depression
severity outcome, while credibility was signiﬁcant for this
outcome in TAU and tends towards signiﬁcance in the CCBT
group. For quality-of-life, only the expectancy factor contributed
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to the outcome in CCBT, and both credibility and expectancy
tend towards signiﬁcance in the TAU group. Credibility and
expectancy do not contribute to the outcomes of the combined
treatment. CONCLUSIONS: Patients’ initial belief about the
success of their depression treatment can inﬂuence the outcome.
Taking the patient’s pre-treatment expectancy and credibility
into account may contribute to a more effective treatment.
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OBJECTIVES: To measure the persistence over time of
intended and unintended effects on community based depres-
sion treatment in the U.S. associated with the FDA warnings on
antidepressants and suicidality. In October 2003 the U.S. FDA
issued a Public Health Advisory about the risk of suicidality for
pediatric patients on SSRI antidepressants; a boxed warning
and medication guide were implemented in February 2005, and
later extended to young adults aged 19–24. Unintended
declines in diagnosis and non-SSRI substitute treatment have
been shown immediately following the advisory both for pedi-
atric patients, and for adult patients not targeted by the warn-
ings. Whether those changes persisted is unknown.
METHODS: Pediatric, young adult, and adult cohorts with
newly diagnosed episodes of depression were created using a
national, integrated managed care claims (commercially avail-
able from PHARMetrics®, a Unit of IMS, Inc.) from July
1999-June 2006 (n = 55,218 youth; 44,141 young adults;
394,524 adults patients with new episodes). Time series analy-
ses compared post-FDA advisory trends to expected trends
based on pre-advisory patterns. RESULTS: Young adult and
adult populations mirrored changes in pediatric depression care
after the FDA advisory. Reductions in national rates of depres-
sion treatment were substantial, returning national diagnosing
rates to 1999 levels for pediatric patients and to 2003 levels for
adults. Primary care providers continued signiﬁcant reductions
in new diagnoses of depression (50% lower for pediatric, 40%
lower for young adult, 30% lower for adult). Substitute care by
psychiatrists or psychologists, psychotherapy, and anxiolytic
and atypical antipsychotic medication use did not signiﬁcantly
change from pre-advisory trends. CONCLUSIONS: Declines in
depression diagnosis continued after the advisory. Substitute
care did not compensate. Spillover to adults continued. Results
suggest that the unintended effects were substantial, diffuse,
and non-transitory in a large national population. Policy
actions are required to counter the unintended consequences of
reduced depression treatment.
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OBJECTIVES: A pilot survey was conducted to determine which
NHS services and resources may possibly be impacted in the
management of adverse events (ADEs) related to antipsychotic
use. METHODS: Ten UK mental health specialists were inter-
viewed. The six-question survey advised participants to assume
that patients’ psychotic symptoms were controlled or that it was
too early in therapy to determine efﬁcacy. The ADEs considered
were limited to those identiﬁed by NICE as most troublesome,
i.e. sedation, extrapyramidal symptoms (EPS), weight gain and
sexual dysfunction. RESULTS: The most common routine tests
performed were: full blood count, glucose, cholesterol and
weight. Action was prompted for sedation and sexual dysfunc-
tion only if the patient raised a concern. For weight gain and EPS,
clinician and patient concerns were given equal consideration.
Actions taken in order of preference were: sedation—decrease
dose, change timing, switch treatment; EPS—decrease dose, add
anticholinergic, switch treatment; weight gain—switch treat-
ment, decrease dose; sexual dysfunction—decrease dose, switch
treatment, add sildenaﬁl. Referrals were mentioned in all
responses but were most commonly associated with weight gain
and sexual dysfunction. Most common tests requested as a result
of an ADE assessment were: glucose, weight, cholesterol and
prolactin. Switching treatment was the most common action in
response to positive tests results for any ADE. CONCLUSIONS:
This pilot survey highlights that ADEs could play a substantial
role in treatment costs given the potential use of resources linked
to their observation, diagnosis and management. As such, in
order to comprehensively calculate the cost-effectiveness of any
antipsychotic treatment, acquisition costs as well as costs asso-
ciated with potential adverse event management should be con-
sidered. To conﬁrm the ﬁndings of this survey, further in-depth
research is warranted.
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OBJECTIVES: To fully describe patients’ characteristics, man-
agement patterns, predictive recurrence factors and economic
impact of health care attention of bipolar patients population in
Spain. The description of the sample of an ongoing cohort study
is being presented. METHODS: Prospective observational
cohort study with a follow-up of 12 months including consecu-
tive outpatients diagnosed of Bipolar Disorder I or II (DSM-IV-
TR), stabilized for at least 2 months, who had at least a mood
disorder episode (depression, mania, hypomania or mixed) in the
last year. RESULTS: A total of 571 patients were included,
60.1% women. Mean age was 47.4 years (SD 13.1). Only 37.5%
were active workers, up to 5.4% were having temporal disability
leave and 16.2% were permanent disabled for working. Regard-
ing study disease, 75% were bipolar I and mean time since
diagnosis was 12.3 years (SD 10.5), although time since ﬁrst
mood episode compatible with bipolar diagnose was 16.3 years
(SD 11.2). Mean mood episode number since disease onset was
10.6 (SD 9.3). Up to 74.1% of patients had been hospitalised
during the disease evolution, mean times were 3.6 (SD 3.3).
21.3% of patients have had a suicide attempt. Regarding the
baseline evaluation, 29.9% of patients were not free of mood
symptoms even being stabilized for at least two months, present-
ing more than two mania symptoms (10.6%) and more than 2
depression symptoms (18.2%). CONCLUSIONS: Even in the
stabilization phase of the disease there is an important symptoms
load. Although depressive symptoms are more frequent than
manic symptoms, both subsyndromal symptoms are present in
euthimic bipolar patients. Bipolar disorder is a relevant chronic
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